Development of inhibitors to coagulation factor VIII or IX is still the most challenging complication in haemophilia care. 'Bypassing agents' may be used to treat a bleed but the eradication of the inhibitor by immune tolerance induction (ITI) is the main objective in the treatment of a patient with haemophilia who has developed neutralizing antibodies. Several options exist for ITI and the patient may be at 'good' or 'bad risk' for successful outcome with different regimens. This paper offers a review of current regimens to be considered in the treatment of a bleed in a patient with an inhibitor but the main focus is the aspects of different choices in the management of the child or the adult with severe or mild forms of haemophilia A or B, who has developed an inhibitor. There are also some final outlooks on new and emerging treatment possibilities.
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Haemophilia A and B are X-chromosomal recessive disorders caused by the deficiency or lack of factor VIII (FVIII) or factor IX (FIX), respectively, in plasma. Depending on the concentration of FVIII or FIX the disorders are classified as severe (FVIII/ IX < 0Á01 U/ml), moderate (0Á01-0Á05 U/ml) or mild (0Á05-0Á40 U/ml). Recombinant or plasma-derived FVIII or FIX concentrate is administered to treat a bleed or, in the more severe forms, administered on a regular basis as prophylactic treatment. Neutralizing antibodies (inhibitors) to FVIII occur in approximately 30% of individuals with severe haemophilia A and to FIX in 2-4% of individuals with haemophilia B, however with a wide frequency range between studies (Wight & Paisley, 2003; Martensson et al, 2016) . Inhibitors usually occur within the 20 first exposure days (Gouw et al, 2013) and are quantified by the Bethesda assay usually with the 'Nijmegen modification' (Verbruggen et al, 1995) . One Bethesda unit
(1 BU) is defined as the amount of inhibitor needed to inactivate 50% of the FVIII/IX present in pooled normal plasma. Depending on the peak inhibitor titre measured with the Bethesda assay, inhibitors are classified as 'low-responding'/ 'low-titre' (<5 BU) or 'high-responding'/'high-titre' (>5 BU). From the clinical point of view, this is a rather useful classification because the inhibitory effect of the low-titre inhibitors can usually be overcome by increasing the dose of FVIII/FIX and no anamnestic response in titre will occur. Some 'low titre' inhibitors are transient and will disappear without treatment while others remain or may progress to high titre. Recent data from the PedNet research study group showed that half of the inhibitors to FVIII that were initially classified as 'low-titre' progressed to 'high titre' when treated with FVIII (Mancuso et al, 2017) . Today, the development of a 'high titre' inhibitor to FVIII or IX is the most serious complication to replacement therapy and renders the patient untreatable with FVIII/IX concentrates. Instead, so called 'bypassing agents', such as recombinant FVIIa (rFVIIa) (Young et al, 2008) and activated prothrombin complex concentrate (aPCC) (Turecek et al, 2004; Astermark et al, 2007) have to be used or, in haemophilia A, there is also the option of recombinant porcine FVIII (Mahlangu et al, 2017) . However, these agents are not as efficient either for treatment of a bleed or as prophylaxis and, furthermore, are less predictable in outcome depending on both the type of bleed and the inter-individual variability in response. Thus, the eradication of the inhibitor by immune tolerance induction (ITI) is the main objective in the treatment of a patient with haemophilia who has developed neutralizing antibodies.
The aim of this review is to give an overview of the choices that the treating physician has in different clinical situations when faced with a haemophilia patient with an inhibitor, and the rationale for different options with a focus on ITI. Haemophilia A and B will be discussed separately as will inhibitors in haemophilia of varying severity.
The child with severe haemophilia A and a newly diagnosed inhibitor without prophylaxis, be at considerable risk of bleed-related arthropathy at an early age, as well as other serious, even life-threatening, bleeds. The main goal of treatment is ITI. There are two principal therapeutic regimens to choose between -the 'Bonn high-dose regimen' or its variant (Brackmann & Gormsen, 1977; Brackmann et al, 1996) and the 'Van Creveld Dutch low-dose' regimen or variant of this . The details of these regimens are given in Table I . Other options could be the 'Malm€ o ITI-protocol' (Nilsson et al, 1983; Freiburghaus et al, 1999) , which includes extracorporeal adsorption of the antibody, a procedure that is not feasible in the youngest children because the extracorporeal blood volume will be too large. Other published series are mainly variants of these principal regimens (Gruppo et al, 1992; Rocino & de Biasi, 1999) .
The International ITI study (Hay & DiMichele, 2012) will give some guidance on whether to choose a high or low dose regimen for the case discussed. This is the first and only randomized controlled study of ITI; it compared high-dose (200 iu/kg/day) and low-dose (50 iu/kg 3 times/week) FVIII regimens in 115 'good-risk' patients with severe haemophilia A and inhibitors with titres 5-200 BU. Successful induction of tolerance, approximately 70%, did not differ between the two treatment arms (24/58 low dose vs. 22/57 high dose, P = 0Á91). However, the times taken to achieve a negative titre (<0Á6 BU) and a normal in vivo recovery (>66% of the expected FVIII concentration after infusion and a FVIII halflife >6 h after a 72-h washout period) were shorter with the high-dose regimen. Furthermore, patients on the low-dose regimen had a mean of 10 bleeds during ITI compared to a mean of 5 for the high dose patients (odds ratio, 2Á2; P = 0Á0019). To me as a paediatric treater, this suggests that a high-dose regimen should be my usual choice for ITI of a high titre inhibitor, given that the time to tolerance, which even with this regimen will be a mean period of around 11-12 months, will be shorter and there will be fewer bleeds. However, I would, in most cases, choose a once daily dose of 100 U/kg as discussed below. It is important to avoid joint bleeds that may trigger the arthropathic process in those subjects, although this is difficult to define on an individual basis, who are more susceptible to developing early changes in the synovia, cartilage and bone after a joint bleed (Lundin et al, 2005; Manco-Johnson et al, 2007; Valentino, 2010) .
The next decision to make is when to start the 'high-dose regimen' and at what dose.
Several registries are on record that make possible an evaluation of variables predictive for successful outcome of ITIthe International ITI registry (Mariani & Kroner, 2001) , the North American registry (Dimichele, 2009) , the German registry (Lenk, 2000) and the Spanish registry (Haya et al, 2001) . However, the conclusions from the different registries are not always in agreement with each other. In all these four registries, an inhibitor titre of <10 BU/ml at ITI onset is recognised as one of the main determinants of ITI outcome, positively affecting both the likelihood of success and the time taken to achieve success. In the Profit study (Coppola et al, 2009 ) a pre-ITI titre <5 BU was also predictive of success. These data suggest that, in patients with high-titre inhibitors but without severe bleeding, the recommendation would be to delay ITI until the inhibitor titre is <10 BU/ml, but preferably within 2 years of inhibitor onset. However, the international randomized ITI-study (Hay & DiMichele, 2012) did not show the pre-ITI titre to be a significant predictor of success and, in clinical practice, many centres have started ITI earlier in patients who have experienced serious bleeds or who have frequent bleeds. This approach has recently been supported by a study (Nakar et al, 2015) showing that tolerance was achieved in 13 patients with an inhibitor titre ≥10 BU/ml despite ITI being initiated within 1 month of inhibitor detection. This study suggests that prompt ITI should be considered a therapeutic option in patients with newly identified FVIII inhibitors, regardless of current inhibitor titre, particularly in those with frequent bleeds. Furthermore, waiting longer before for a successful ITI means a longer period of on-demand treatment and thus an increased risk of an intracranial bleed (Andersson et al, 2017) .
In the original Bonn protocol, the FVIII dose was 100-150 U/kg twice per day, with additional aPCC 50 U/kg twice daily for those at high risk of bleeding (Brackmann & Gormsen, 1977) . The International ITI study, including 'good risk' patients, used 200 U/kg once per day and other studies/registries have shown good results with 100 U/kg/day (Mariani et al, 1994; Rocino et al, 2001; DiMichele & Kroner, 2002) . A meta-analysis of the International and North American registries did not find an impact of the dose of FVIII for patients with historical peak titre <200 BU or pre-ITI titre <10 BU, further supporting the concept that we do not know the optimal 'high dose' (Kroner, 1999) . Unfortunately, there are no 'head to head' randomized comparisons between different 'high-dose' regimens. One must take into consideration that a twice-daily regimen is a burden for the patient, particularly given that these patients are often children in need of a central venous line. The cost of a 'high-dose' regimen is extremely high and one has to be able to justify the benefit of doubling the dose from 100 to 200 U/kg in the first ITI treatment period, especially in 'good risk' patients. Due to the lack of evidence showing that 200 U/kg is more successful (Kroner, 1999; Holstein et al, 2016) , the recommendation would be to use 100 U/kg in all cases and if a higher dose is perceived to be needed, rather administer two daily doses of 100 U/kg (Kreuz et al, 2016) .
If a child has developed a low titre inhibitor it may be transient and disappear within a few months. If the child is on prophylactic therapy my choice would be to continue regular administration of FVIII but at a higher dose (50 U/kg every other day) which will offer both a 'low-dose' ITI and some prophylactic effect (Ter Avest et al, 2010) . The inhibitor may switch to a 'high-titre' and must then be treated as discussed above.
The 'good risk' and 'bad risk' patient Table II shows the suggested predictors of successful ITI outcome. The above discussion regarding the choice of ITI regimen for the 'good risk' patient, i.e. historical peak <100 BU (Oldenburg et al, 1999; Rocino et al, 2001; Ragni et al, 2009) or <200 U/kg (Kroner, 1999; Lenk, 2000) , peak titre during ITI <100 BU (Coppola et al, 2009 ) and pre-ITI titre <10 BU (Lenk, 2000; Haya et al, 2001; Mariani & Kroner, 2001; DiMichele & Kroner, 2002) , is reasonably evidence based. Should the 'high risk' patient be treated differently in the first course of ITI? Outcome of ITI in 'bad risk' patients in registries and the literature suggest that these patients need another regimen. If we look at the historical peak inhibitor titre, tolerance was achieved in 82% if <50 BU but only in 52% in the International registry (Mariani & Kroner, 2001) and 21% in the North American registry (DiMichele & Kroner, 2002) if peak was >200 BU. Also, the German and Spanish registries and the Profit study show a similar inverse relationship between peak historical titre and success of ITI (Lenk, 2000; Haya et al, 2001; Coppola et al, 2009) . Older age at start of ITI may also be a negative factor but divergent results can be found in different studies (Oldenburg et al, 2014) . However, it may be that it is not age itself, but the time that has elapsed between the occurrence of the inhibitor and start of ITI that matters. Data in the literature support that it is beneficial to start within 5 years after the diagnosis of an inhibitor (Mariani & Kroner, 2001; DiMichele & Kroner, 2002) . The type of mutation has also been shown to have an impact on the outcome of ITI. Experiences with the Bonn protocol (Oldenburg et al, 1999) showed that there was a tendency towards longer ITI duration in patients exhibiting the prevalent intron 22 inversion, a finding also supported in an Italian series (Salviato et al, 2007) . The same pattern was also found in the Profit study (Coppola et al, 2009) where 81% (13/16) with missense/small indels were tolerized compared to 47% (33/70) with nonsense or large deletions (P = 0Á01). Ethnicity has also been discussed but with diverging results. The North American registry did not show any impact of ethnicity while another single centre report from the USA showed significantly better results in non-black versus black patients [92% (11/12) vs. 58% (13/ 23)] (Callaghan et al, 2011) .
It is quite clear that we have good data to classify a patient with haemophilia A and a newly diagnosed inhibitor to be a 'good' or 'bad' candidate for ITI but the question remains if one should treat them differently in the first course of ITI. For the first course of ITI most treaters would use the same concentrate that provoked the inhibitor (Dimichele et al, 2004; Valentino et al, 2015) . A recent survey conducted in 16 European centres showed that 87% of the physicians would give the same product in first line ITI to a child and slightly fewer, 74%, to an adult as first line ITI (Holstein et al, 2016) . Some publications, mainly from Germany, suggest that a plasma-derived concentrate with high content of von Willebrand factor (VWF) may give a better outcome (Kreuz, 2008; Escuriola Ettingshausen & Kreuz, 2014; Kreuz et al, 2016) . The Observational Immune Tolerance Induction (ObsITI) study showed complete success in 63% of patients with at least one 'bad risk' factor by use of a plasma-derived concentrate (Kreuz et al, 2016) . However, a recent meta-analysis including 13 studies evaluating 382 patients did not demonstrate a difference in the proportion of patients with successful inhibitor eradication between those treated with VWF-containing products and those treated with FVIII concentrates devoid of VWF {relative risk [RR] 0Á70 [95% confidence interval (CI) 0Á52-0Á89] and 0Á84 [95% CI 0Á75-0Á93], respectively} (van Velzen et al, 2014) . Thus, it seems that the 'bad risk' patient needs something more than a higher and more frequent dose of a plasmaderived VWF-containing concentrate.
Immunomodulation is not usually used in first line ITI treatment but is reserved for those not responding. However, it may be time to re-evaluate given that we have more experiences and also new immune modulating agents. A systematic review of 29 studies that included 49 cases treated with rituximab (an antibody that reacts with the CD20 antigen on B-lymphocytes) showed a durable complete remission in 53% of the cases and no severe adverse events related to rituximab (Franchini et al, 2008) , which is similar to the 58% response obtained in a UK series (Collins et al, 2009) . In these studies, FVIII was administered concomitantly at a high dose with rituximab. Rituximab as a single drug is not useful for ITI but can be used to lower the anamnestic response of high titre inhibitors, as shown in the RICH study in the USA where 3/16 met the criteria for a major response, defined as a fall in inhibitor titre to <5 BU, persisting after FVIII re-challenge (Leissinger et al, 2014) . Rituximab has usually been administered in a dose of 375 mg/m 2 once weekly for 1-4 weeks. Intravenous gammaglobulin together with FVIII has been reported in a few case reports with positive results (de Cos & Rodriguez-Martorell, 2014; Kubisz et al, 2015) . The first reported use of an ITI regimen using intravenous gammaglobulin was in the 'Malm€ o-protocol' where it was used together with protein-A adsorption of immunoglobulin G (IgG) in plasma and with cyclophosphamide and FVIII (Nilsson et al, 1988) . In the original report of this method, the inhibitors disappeared after 2-3 weeks of the combined treatment in 9/11 patients and the half-life of infused FVIII normalized in 8/9. This method is no longer used much in congenital haemophilia due to the complicated procedures with extracorporeal adsorption, but remains as an alternative in selected cases. Beutel et al (2009) presented a successful tolerance induction in a patient with haemophilia B using a combination of rituximab (375 mg/ m 2 four weekly courses), mycophenolate mofetil (MMF; 2 9 300 mg/m 2 daily for 7 weeks), dexamethasone (pulses with very high doses; 2 9 12 mg/m 2 total 10 administrations), intravenous immunoglobulins (1 g/kg 2 days on three occasions) and high-dose FIX. The author has also used this protocol for second-line treatment in children refractory to the first treatment regimen and is also aware of several cases using this method both as first-and second-line treatment with rather good results with either complete or partial remissions. It was obvious in a recent survey of European centres that immune suppression, of various kinds, was used almost exclusively for those with inhibitors >200 BU (Holstein et al, 2016) but its use did not seem to increase between surveys conducted in 2004 and 2016. To sum up the suggested treatment for a 'bad risk' patient, it is tempting to add some kind of immune modulating therapy in the first ITI attempt, given that we may otherwise expect a poor response. However, this should be done using an agreed specific protocol enabling its use in several centres and reporting to a registry or similar to be able to merge results for a more structured scientific evaluation of adding immune modulation. As for now, one should probably start with a conventional ITI, i.e. as suggested above 100 U/kg/day, also in these 'bad risk' patients but be prepared to switch much earlier to a regimen including immune modulation at the first signs of refractoriness (such as no signs of decline of titre after 3-6 months).
When should ITI be stopped?
When to stop the ITI depends on the aim of the regimen. The ultimate aim is, of course, successful tolerance induction, which means eradication of the inhibitor. A widely adopted definition of successful ITI, established by consensus at the Second International Conference on Immune Tolerance in Bonn [unpublished but later further developed by DiMichele et al (2007) , includes (i) A negative inhibitor titre (≤0Á6 BU by Bethesda or Nijmegen assays) and (ii) normalized FVIII pharmacokinetics (defined as plasma FVIII recovery ≥66% of expected and FVIII half-life >7 h after a 72-h FVIII washout period). However, many patients may not reach total eradication of the inhibitor but a status designated 'partial success' which in the International ITI study (Hay & DiMichele, 2012) was defined as an undetectable inhibitor titre, but with a persistently abnormal FVIII recovery or half-life after 33 months of ITI, which allows conventional prophylaxis to be continued without an anamnestic response. In some cases, it may even be an inhibitor with a measurable low titre that can be neutralized by higher than usual doses of FVIII both for treatment of a bleed but also as a daily prophylactic treatment. This situation has been covered by a slightly different definition of partial success : a reduction of the inhibitor titre to <5 BU, FVIII recovery <66% of expected, FVIII half-life <6 h after a 72-h washout period and no anamnestic response over a 6-month period and a clinical response to FVIII. The latter definition of partial response is clinically useful and often used in the author 0 s practice. Both success and a partial success may justify stopping the ITI regimen and switching gradually to a prophylactic regimen of 50-25 U/kg daily and later on every second day according to patient need. A more difficult question is when to define the ITI attempt as a failure and stop it. According to the consensus established at the Second International Conference on Immune Tolerance and the International ITI study (Hay & DiMichele, 2012) , failure is defined as: (i) Failure to achieve the definition of success or partial response within 33 months, or (ii) The inability to achieve a 20% reduction in inhibitor titre during each successive 6-month period of uninterrupted ITI, after the first 3 months of ITI. This definition implies a minimum ITI duration of 9 months and a maximum of 33 months before failure can be declared and does not allow for any improvement in the clinical phenotype that may occur after initiating ITI. When asked in a European survey of 16 centres, there was a broad range of 3-36 months in the time that the treating physician would continue ITI before considering it to have failed (Holstein et al, 2016) . A modified Delphi approach with surveys to reach a consensus was carried out in Australian clinical practices with regard to ITI (Barnes et al, 2014) . The consensus identified the clinical outcomes as important factors for assessing ITI response and suggested that the trend in inhibitor titre may be more helpful in assessing response to ITI than the absolute titre. Assessment over any 3-to 6-month period without a 20% reduction in inhibitor titre was suggested as failure, but a reduction in bleeding phenotype alone was considered a sufficient reason to continue ITI. Overall, they concluded that a period of 3 or 5 years of ITI may be required to determine response to ITI. Alternative clinical endpoints of when to stop have also been suggested by the UK Haemophilia Centre Doctors Organization, who defined success according to whether FVIII half-life is >7 h after a 72 h washout period or the FVIII trough level is ≥1% 48 h after a dose of ≤50 iu/kg (Hay et al, 2000; Collins et al, 2013 ) (=conventional prophylaxis possible).
The ideal situation is that the treatment will result in eradication of the inhibitor and fulfilment of the criteria for success. However, in the author's view (and partly supported in the literature Hay & DiMichele, 2012; Valentino et al, 2015) , it is reasonable to reconsider an ongoing treatment in a patient who has not shown any decline in inhibitor titre of >20% during a 6-month period. In this situation, some change in the current regimen should be made, such as changing the FVIII concentrate, administering the treatment twice daily or at a higher dose or adding some kind of immune modulator, such as rituximab. One should also consider stopping ITI in those who level off at an inhibitor level (i.e. usually <5 BU) that is sufficient for a FVIII concentrate to be given in enough concentration to stop a bleed or if there is a period of measurable FVIII after a daily prophylactic administration (i.e. partial response). In the latter case, one may administer FVIII at a dose of 50 U/kg daily in the morning which will give a rather acceptable prophylactic effect during the active daytime hours and at the same time act as a continued 'low dose' ITI. Such an approach will be cost-saving compared to continuing a high-dose regimen that, according to the International ITI-study, will have the same end result of success. The increased risk of bleeds with the low-dose regimen is eliminated because the 'partial response titre' will not immediately neutralize the dose given. If, in this situation, the titre starts to raise again, the author has good experience with the administration of a once weekly dose of rituximab (375 mg/m 2 ) for 1-2 weeks as a single agent to keep the titre low for 6-12 months, after which, when needed, a single dose of rituximab may prolong the effect. A successful or partly successful ITI should always be continued by daily or every second day regular prophylactic treatment. In case of failure, a new attempt should be made with a different regimen, preferably with some kind of immune modulation. In a European survey, over 90% of the treating physicians would make a new attempt after 1-2 years; most of them would use a plasma-derived VWFcontaining concentrate and half of them would include adjuvant immune suppression (Holstein et al, 2016) . It seems, in the lack of solid data, theoretically reasonable to let the immune system 'cool down' after a failed ITI attempt. The inhibitor risk at 50 exposure days was 6Á7% (95% CI, 4Á5-8Á9) and at 100 exposure days the risk increased to 13Á3% (95% CI, 9Á6-17Á0). Furthermore, it was found that 19 out of the 214 mutations found in the cohort were risk mutations for development of inhibitors. The most prevalent amino acid substitutions were Arg593Cys (9%), Arg2150His (5%), Asn618Ser (5%) and Arg531Cys (3%). This emphasizes that genotyping of mild haemophilia should be performed, making it possible to define a risk group for development of inhibitors where one should, if possible, avoid treatment with FVIII concentrates and instead use desmopressin (DDAVP). It has also been shown that intensive treatment, for example in conjunction with surgery, will increase the risk, as has also been shown for severe haemophilia A (Gouw et al, 2013; van Velzen et al, 2017) . The development of inhibitors in mild haemophilia A is a serious complication and it has been shown that the all-cause mortality rate in inhibitor patients was >5 times increased compared with that for those without inhibitors . Inhibitors in mild haemophilia may be different from the ones in severe haemophilia A and sometimes show so-called type II kinetics similar to the autoimmune disorder acquired haemophilia (Luna-Zaizar et al, 2009 ). This may have implications for the treatment and some inhibitors clearly distinguish wildtype from self-mutated FVIII (Peerlinck et al, 1999; Luna-Zaizar et al, 2009) . The INSIGHT study is the largest observational study on record on mild haemophilia A and it included 101 inhibitor patients (median peak titre 7 BU/ml, IQR 2-30) from a population of 2709 non-severe haemophilia A patients (FVIII 2-40 iu/dl), treated in Europe and Australia (median age 37 years, IQR 15-60) . In the majority of the patients (71%; 72/101) the inhibitor disappeared; either spontaneously (70%, 51/73) or after eradication treatment (75%, 21/28). Inhibitors disappeared spontaneously after a median of 15 months (IQR 7-38) and after nine months in the treated group (IQR 3-16) (P = 0Á087). However, sustained success was achieved only in 64% (30/47) of those patients re-challenged with FVIII concentrate. In hightitre inhibitor patients sustained success was associated with eradication treatment (unadjusted RR 2Á3, 95% confidence interval 1Á3-4Á3), compared to no eradication treatment. There was no difference in outcome between those with measurable endogenous FVIII compared to those without measurable FVIII so this parameter cannot be used to guide treatment. In addition, the inhibitor titre, low or high, did not differentiate between those patients in whom the inhibitor disappeared spontaneously or after treatment. To summarise, for on mild haemophilia it is not currently possible to define a risk group with inhibitors that need to be treated with ITI based on the FVIII level or the titre of inhibitor or the mutation causing the mild haemophilia. The clinical circumstances with bleeding tendency will probably guide which patients may benefit from shortening the time from diagnosis of the inhibitor to eradication, which may be the main benefit of treatment. In patients without bleeds the advice would be to 'wait and see', at least for the median time for spontaneous disappearance. If treatment is needed it seems likely that this group may need some kind of immune suppression and rituximab has shown documented effect in a multi-variant analysis of a cohort of 36 patients with mild or moderate haemophilia A and inhibitor (Kempton et al, 2012) . In this analysis, rituximab alone (n = 6) and other immune-modulating treatments alone (n = 2) were significantly associated with an increased likelihood of inhibitor clearance [hazard ratio (HR) = 4Á4 (95% CI = 1Á06-20Á03) and 10Á21 (95% CI = 1Á17-78Á28), respectively], whereas ITI alone (n = 9) was not [HR = 1Á35 (95% CI = 0Á44-4Á07)]. However, it is not known if the result was sustained after rechallenge with FVIII. Treatment of mild haemophilia with inhibitors is thus a challenge and emphasizes once more the need for consensus protocols used in centres globally, with treatment and outcome data collected in a uniform way to allow future evaluation.
ITI in mild/moderate haemophilia A

ITI in haemophilia B
ITI is haemophilia B is even more challenging than in haemophilia A. Inhibitors occur in 2-4% of patients with severe haemophilia B in most published series; 4Á7% of 169 patients in an Italian series (Belvini et al, 2005) , 2Á1% among 142 in a Canadian series (Webert et al, 2012) and 1Á3% among 153 in a series from the USA (Miller et al, 2012) . A much higher frequency has been reported from Sweden, 19% of those with severe haemophilia B had developed inhibitors (Martensson et al, 2016) and a similar result, 17%, was also found in the series by Li et al (2014) . The pathophysiology and risk factors of inhibitors in haemophilia B is much less known than in haemophilia A and patients may develop IgE antibodies that are usually detected at the same time and will provoke an allergic/ anaphylactic reaction (Warrier et al, 1997; Chitlur et al, 2009; Goodeve, 2015) . About half of these patients have total gene deletions or large derangements of the F9 gene (Warrier et al, 1997) . A nephrotic syndrome may occur usually after almost a year of high dose FIX treatment (Warrier et al, 1997) .
There are no large series on record with regard to ITI in haemophilia B. The North American Registry reported data on 16 patients, with success in 25% and about half of them had immune suppressive therapy (DiMichele & Kroner, 2002; Dimichele, 2009 Castaman et al (2013) reported 8/282 with inhibitors in an Italian survey, of whom 4/5 had a successful ITI without nephrotic syndrome. Several case reports with the use of rituximab have been published (Mathias et al, 2004; Chuansumrit et al, 2008; Barnes et al, 2010; Ranta et al, 2012) , usually with high doses of FIX but sometimes with various combinations of MMF (Klarmann et al, 2008) , corticosteroids and/or intravenous IgG and with lower doses of (40 iu/kg) FIX. The Malm€ o protocol has been successful in 6/7 (86%) of cases of severe haemophilia B (Freiburghaus et al, 1999) . In this method, the dose of FIX is administered frequently with the aim to keep a measurable FIX all the time after adsorption of the antibody in plasma.
The experiences from ITI in haemophilia A cannot be transferred directly to haemophilia B. It is obviously more difficult to achieve tolerance in haemophilia B and the optimal dose of FIX in ITI is not known, but daily doses of 50-100 U/kg FIX depending on inhibitor titre could be tried. However, one should be aware of the risk of nephrotic syndrome after long-term administration with high doses of FIX, particularly in those with large gene deletions and previous anaphylactic reaction. The protocol described by Beutel et al (2009) , used by the author with success in two out of two cases with haemophilia B inhibitors and anaphylaxis and other cases on record (unpublished observations), seems promising for both eradication of inhibitor and desensitisation. The role of the new extended half-life (EHL) FIX needs to be investigated too (Powell et al, 2013; Negrier et al, 2016; Santagostino et al, 2016) . As the half-life of EHL-FIX is prolonged 4-5 times, administration could, perhaps, be less frequent, thus facilitating treatment. Currently, we have hardly any experience of EHL products used in ITI.
Aspects of ITI in adults
Most inhibitors occur early in life after the first 20-50 exposure days, but inhibitors occur throughout life with a bimodal risk, being greatest in early childhood and in old age. In the UK, the age-adjusted incidence of new FVIII inhibitors was analysed in all patients with severe haemophilia A between 1990 and 2009 (Hay et al, 2011) . A total of 315 new inhibitors were reported in 2528 patients who were followed up for a median (IQR) of 12 (4-19) years. Of these, 160 (51%) arose in patients ≥5 years of age after a median (IQR) of 6 (4-11) years follow-up. ITI in adults should follow the general principles outlined above, but of particular concern are the high costs related to ITI in adults, as these patients require considerably larger quantities of factor than children. Cost analysis of ITI versus on-demand and prophylactic therapy has been made and showed that treating patients to eradicate inhibitors may result in lower lifetime costs and greater quality-adjusted life-years than treating with bypassing agents (Earnshaw et al, 2015) . Most physicians would agree that ITI should be considered in adults (Rangarajan et al, 2014) , as older age when starting ITI may not adversely affect the outcome in patients with recent-onset inhibitors arising in adulthood. Furthermore, in a multivariable analysis, the odds of death were 70% higher among patients with a current inhibitor compared to those without an inhibitor (P < 0Á01) and deaths were more likely to be caused by bleeds (Walsh et al, 2015) . Taken together, the current data suggest that at least one course of conventional ITI may be justified in adults with high or low titre inhibitors in countries in which health care resources allow its use and a 'lowdose' regimen may considerably reduce the costs.
Treatment and prophylaxis of bleeds in patients with inhibitors
Bleeds in patients with low-titre inhibitors can usually be managed by increased doses of FVIII/IX to overcome the neutralizing effect of the antibody. The choice between the two 'bypassing' agents depends on several factors. Recombinant activated factor VII (rFVIIa) (Hedner & Kisiel, 1983; Young et al, 2008) has a half-life of approximately 2 h in plasma and is administered by an injection of a small volume: 90 lg/kg 9 3 has been shown to have equal effect to 270 lg/kg. aPCC is a plasma-derived product with its theoretical risk of transmitting infectious agents (although this has never been shown), which needs to be administered in a larger volume via an infusion and contains FVIII, which may give an anamnestic response. However, the functional halflife is considered to be 4-7 h. The FENOC (FEIBA NovoSeven Comparative) study randomized these two therapeutic bypassing agents in a cross-over design and showed them to have equal efficacy, but 30% of the patients in the study preferred one of the products over the other. These agents should be administered as soon as possible after symptoms of a bleed but do not control bleeds as well as FVIII/FIX concentrates and the effect is sometimes unpredictable; this is problematic as we do not have any simple laboratory method to monitor the effect. In cases of severe bleeding not responding adequately, a combination of the two bypassing agents has been used either concomitantly or in a sequential manner (Schneiderman et al, 2004) . Combining FVIII with aPCC or rFVIIa has shown a promising effect in terms of thrombin generation (Livnat et al, 2008 (Livnat et al, , 2017 but the doses to be recommended in clinical practice need to be defined. Bypassing agents have also been used as regular prophylaxis, which is very expensive; it reduces the number of bleeds but does not make the patient bleed-free (Konkle et al, 2007; Young et al, 2012; Antunes et al, 2014) .
Anti-fibrinolytic therapy with tranexamic acid or epsilon aminocaproic acid can be recommended as adjuvant therapy, especially in patients with bleeds in mucous membranes. The author often uses tranexamic acid as adjuvant treatment in patient with inhibitors; however, a thrombotic event has been reported in an adult with F5 R506Q (FV Leiden mutation) (Gunaldi et al, 2009) . The author has also used tranexamic acid in a very low dose (25-35% of usual dose 9 2-3 for 1-2 days) with a very fast-acting and good effect in several cases of bleeds in the urinary tract in children who are un-responsive to intensive treatment with bypassing agents.. However, these patients have a considerable risk of developing a clot in the urinary system, which has to be monitored carefully with ultrasound during the treatment.
The future of ITI and conclusions
Regular administration of FVIII and FIX to desensitize the immune system has been the main method of eradicating inhibitors for several decades since the pioneering discovery by Brackmann and Gormsen (1977) . In the future, we may learn more about the immunization process and be able to introduce the factors in a way that they will be tolerated. Engineered T-cell therapies may be a way to induce FVIIIspecific tolerance (Parvathaneni et al, 2017) . Three new promising concepts of treating haemophilia, irrespective of inhibitors, are now in the final developmental stages before being licensed and introduced in routine care. Emicizumab is a humanized bispecific antibody mimicking the cofactor function of FVIII (i.e. not useful in haemophilia B) (Shima et al, 2016) , concizumab is a monoclonal antibody targeting the tissue factor pathway inhibitor (TFPI) (Chowdary et al, 2015) and the third, Fitusiran, acts by RNA interference (RNAi) of anti-thrombin (Pasi et al, 2017) . All can be administered subcutaneously and less frequently compared to the current intravenous concentrates and may, hopefully, represent a paradigm shift of treatment for patients with inhibitors. However, for the time being, we will still need to eradicate inhibitors to FVIII/FIX. Optimizing and individualizing the ITI regimens will continue to be a challenge in haemophilia care, with the need for collaboration and evaluation of protocols agreed after consensus discussions.
